M. Mirza
New England Journal of Medicine · 2011–2023
A researcher in the Science corpus: 10 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from M. Mirza's perspective
Ordered by how strongly the researchers M. Mirza trusts endorse each paper. Same corpus, a different order for every researcher.
- Integrated Genomic Characterization of Endometrial Carcinoma (Nature)
- Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (Annals of Oncology)
- A clinically applicable molecular-based classification for endometrial cancers (British Journal of Cancer)
- Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. (The Lancet)
- Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium
- Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial
- Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. (Gynecologic Oncology)
- Post operative radiation therapy in endometrial carcinoma : reducing overtreatment and improving quality of life
- Comparative Study
- Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts (Clinical Cancer Research)
Their papers
- Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. (2014) — 1,477 citations
- A phase 3 trial of bevacizumab in ovarian cancer. (2011) — 2,021 citations
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. (2023) — 612 citations
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma (2020) — 1,756 citations
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019) — 610 citations
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (2019) — 1,774 citations
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. (2016) — 2,122 citations
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial (2015) — 794 citations
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2015) — 904 citations
- ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. (2015) — 642 citations